- Home
- PRPO vs MBIO Comparison
PRPO vs MBIO Comparison
Compare PRPO & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- MBIO
- Stock Information
- Founded
- PRPO N/A
- MBIO 2015
- Country
- PRPO United States
- MBIO United States
- Employees
- PRPO N/A
- MBIO N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- PRPO Industrials
- MBIO Health Care
- Exchange
- PRPO Nasdaq
- MBIO Nasdaq
- Market Cap
- PRPO 9.9M
- MBIO 7.3M
- IPO Year
- PRPO N/A
- MBIO N/A
- Fundamental
- Price
- PRPO $6.65
- MBIO $2.81
- Analyst Decision
- PRPO
- MBIO Strong Buy
- Analyst Count
- PRPO 0
- MBIO 1
- Target Price
- PRPO N/A
- MBIO $100.00
- AVG Volume (30 Days)
- PRPO 6.8K
- MBIO 411.9K
- Earning Date
- PRPO 03-28-2025
- MBIO 03-10-2025
- Dividend Yield
- PRPO N/A
- MBIO N/A
- EPS Growth
- PRPO N/A
- MBIO N/A
- EPS
- PRPO N/A
- MBIO N/A
- Revenue
- PRPO $17,411,000.00
- MBIO N/A
- Revenue This Year
- PRPO $75.18
- MBIO N/A
- Revenue Next Year
- PRPO N/A
- MBIO N/A
- P/E Ratio
- PRPO N/A
- MBIO N/A
- Revenue Growth
- PRPO 31.31
- MBIO N/A
- 52 Week Low
- PRPO $4.31
- MBIO $2.71
- 52 Week High
- PRPO $7.20
- MBIO $74.50
- Technical
- Relative Strength Index (RSI)
- PRPO 63.80
- MBIO 28.00
- Support Level
- PRPO $6.52
- MBIO $3.96
- Resistance Level
- PRPO $6.90
- MBIO $6.70
- Average True Range (ATR)
- PRPO 0.27
- MBIO 0.97
- MACD
- PRPO 0.03
- MBIO -0.12
- Stochastic Oscillator
- PRPO 89.90
- MBIO 2.83
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.